Repurposing of FDA-approved drugs using CADD to inhibit T1D-related gene MST1
Session Number
2
Advisor(s)
Dr. John Thurmond, IMSA
Location
A131
Discipline
Chemistry
Start Date
15-4-2026 11:10 AM
End Date
15-4-2026 11:55 AM
Abstract
Type 1 Diabetes is a chronic illness that affects a large population of people in the world today. MTS1 is a gene associated with Type 1 Diabetes and has been identified as a high-importance 63 target for treatment. The gene is pertaining to degradation of the amount of insulin secretion taking place within the body. Inhibiting the MST1 gene would increase insulin secretion, which would make a large difference for diabetic patients. This study uses repurposing, which is the drug discovery technique of using pre-existing drugs to treat a disease other than the one it was designed for. It also uses CADD (Computer Aided Drug Design) on the program Seesar, which allows for visualization of protein structures, the identification of binding sites, and docking techniques. On Seesar, a protein structure of MST1 was identified with the PDB code 3COM. Using a database of FDA-approved drugs and testing their binding affinity to the 3COM structure, it was determined which drugs could potentially be used to inhibit the MST1 gene. Results will be presented.
Repurposing of FDA-approved drugs using CADD to inhibit T1D-related gene MST1
A131
Type 1 Diabetes is a chronic illness that affects a large population of people in the world today. MTS1 is a gene associated with Type 1 Diabetes and has been identified as a high-importance 63 target for treatment. The gene is pertaining to degradation of the amount of insulin secretion taking place within the body. Inhibiting the MST1 gene would increase insulin secretion, which would make a large difference for diabetic patients. This study uses repurposing, which is the drug discovery technique of using pre-existing drugs to treat a disease other than the one it was designed for. It also uses CADD (Computer Aided Drug Design) on the program Seesar, which allows for visualization of protein structures, the identification of binding sites, and docking techniques. On Seesar, a protein structure of MST1 was identified with the PDB code 3COM. Using a database of FDA-approved drugs and testing their binding affinity to the 3COM structure, it was determined which drugs could potentially be used to inhibit the MST1 gene. Results will be presented.